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Tumor protein 53-induced nuclear protein 1 (TP53INP1) is a stress-induced p53-target
gene whose expression is modulated by transcription factors such as p53, p73, and E2F1.
TP53INP1 gene encodes two isoforms of TP53INP1 proteins, TP53INP1α and TP53INP1β,
both of which appear to be key elements in p53 function. In association with homeodomain-
interacting protein kinase-2 (HIPK2), TP53INP1 phosphorylates p53 protein at Serine-46.
This enhances p53 protein stability and its transcriptional activity, leading to transcriptional
activation of p53-target genes such as p21 and PIG3, cell growth arrest and apoptosis upon
DNA damage stress.The anti-proliferative and pro-apoptotic activities ofTP53INP1 indicate
that TP53INP1 has an important role in cellular homeostasis and DNA damage response.
Deficiency inTP53INP1 expression results in increased tumorigenesis, whereasTP53INP1
expression is repressed during early stages of cancer by factors such as miR-155. This
review aims to summarize the roles of TP53INP1 in blocking tumor progression through
p53-dependant and p53-independent pathways, as well as the elements which repress
TP53INP1 expression, hence highlighting its potential as a therapeutic target in cancer
treatment.
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INTRODUCTION
The TP53 gene encodes for the p53 protein which modulates target
gene expression, regulates cell cycle progression and apoptosis, and
functions as a tumor suppressor. p53 has been described as “the
guardian of the genome,” due to its role in conserving stability by
preventing the occurrence of mutation in the genome (Strachan
and Read, 1999).
One of the key target genes of p53 is tumor protein 53-induced
nuclear protein 1 (TP53INP1). TP53INP1 is expressed in many
tissues upon exposure to various stress agents, and encodes two
nuclear isoforms, TP53INP1α and TP53INP1β, both of which
appear to be key elements in p53-mediated cell cycle arrest and
apoptosis in different cell types (Tomasini, 2003). As a tumor sup-
pressor, TP53INP1 has been reported to be down-regulated in
cancers from different organs (Jiang et al., 2006; Gironella et al.,
2007; Shibuya et al., 2010).
Tumor protein 53-induced nuclear protein 1 gene localizes to
human chromosome 8q22 (Nowak et al., 2005), which shows
sequence conserved with the A1–A2 of the murine chromo-
some 4 where the mouse TP53INP1 has been mapped (Carrier
et al., 2000). Sequence analysis by the HUGO Gene Nomenclature
Committee has revealed that stress-induced protein (SIP), p53-
dependent damage-inducible nuclear protein 1 (p53DINP1), and
thymus-expressed acidic protein (TEAP) are all in fact TP53INP1.
Tumor protein 53-induced nuclear protein 1 was first cloned
and characterized in an attempt to identify pancreatic genes
induced by the cellular stress acute pancreatitis in mouse, using a
quantitative fluorescent cDNA microarray hybridization approach
(Tomasini, 2001). The mouse TP53INP1 gene is almost 20 kb
pairs in length with five exons. The exon 4 of 28 base pairs
is alternatively spliced to generate two transcripts which trans-
lates into two nuclear proteins of 18 and 27 kDa, SIP18 and SIP27
(Tomasini, 2001) corresponding to TP53INP1α and TP53INP1β
respectively (Tomasini, 2003). TP53INP1α and TP53INP1β pro-
teins differ in their C-terminal region and can promote apoptotic
cell death when overexpressed (Tomasini, 2001). Both TP53INP1α
and TP53INP1β are rapidly and strongly induced in pancreatic aci-
nar cells during the acute phase of pancreatitis and the exposure
to various stress agents such as UV, DNA base damaging, ethanol,
heat shock, and oxidative stress.
In this review, we aim to summarize the mechanisms through
which TP53INP1 blocks tumor progression via p53-dependant
and -independent pathways, and the mechanisms through which
TP53INP1 gene expression is suppressed in cancer. Additionally,
we will discuss the diverse functions of TP53INP1 in cancer such
as induction of autophagy and repression of tumor cell migra-
tion, and highlight its potential as a therapeutic target in cancer
treatment.
TP53INP1 FUNCTIONS AS A TUMOR SUPPRESSOR AND
INDUCES APOPTOSIS THROUGH PHOSPHORYLATING p53 AT
SERINE-46
Multiple lines of evidence suggest that TP53INP1 gene expres-
sion is modulated by p53. Firstly it has been shown that cells with
deleted, mutated, or inactive p53 are unable to activate TP53INP1
gene expression in response to stress agents (Tomasini et al., 2002).
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Secondly mouse embryo fibroblasts transformed with rasV12/E1A
has shown stronger induction of TP53INP1 mRNA expression by
activating p53-dependent pathway, compared to fibroblasts with-
out p53 activity (Tomasini et al., 2002). Both observations suggest
that TP53INP1 gene expression is activated by p53 in response to
stress or transformation in cells expressing wild-type p53.
Tumor protein 53-induced nuclear protein 1 phosphorylates
p53 at Serine (Ser)-46 by forming protein complexes with the pro-
tein kinase homeodomain-interacting protein kinase-2 (HIPK2)
or protein kinase C δ (PKCδ) (Figure 1). HIPK2, a member of a
novel family of nuclear serine/threonine kinases, co-localizes with
p53 and PML-3 in the nuclear bodies and is activated after irradia-
tion with ultraviolet. HIPK2 directly interacts with p53 and phos-
phorylates p53 at Ser-46, leading to p53-target gene transcription
and the activation of p53-dependent apoptosis pathway (D’Orazi
et al., 2001; Hofmann et al., 2002). Further analysis of subcel-
lular distributions showed that p53, HIPK2, TP53INP1α, and
TP53INP1β all localize into the pro-myelocytic leukemia nuclear
bodies, PML-NB, which are cell cycle-regulated nuclear structures
appearing as punctate foci in interphase nuclei (Tomasini, 2003).
Such co-localization facilitates the protein interactions by posi-
tioning the resulting complex near its site of action (Tomasini,
2003). Importantly, both TP53INP1α and TP53INP1β in associ-
ation with HIPK2 regulate p53 transcriptional activity on p21,
PIG3, and BAX promoters, induce G1 cell cycle arrest and increase
p53-mediated apoptosis (Tomasini, 2003).
In another study, Yoshida et al. (2006) have demonstrated that
PKCδ, another kinase from the family of nuclear serine/threonine
kinases, also associates with p53 and mediates its phosphorylation
at Ser-46 upon exposure to genotoxic agents, hence promot-
ing p53-mediated apoptosis in cellular response to DNA damage
(Yoshida et al., 2006). Moreover,PKCδ functions as a protein kinase
and physically binds to TP53INP1 upon genotoxic stresses, leading
to the formation of the PKCδ-TP53INP1 protein complex to regu-
late p53 protein phosphorylation at Ser-46 as well as p53-induced
apoptosis (Yoshida et al., 2006).
The induction of growth inhibition and apoptosis is one of the
most important tumor suppressive functions of p53. The challenge
to find the exact mechanisms of p53-dependent apoptosis remains
ongoing. In 2000, it was shown by Oda et al. (2000) that phospho-
rylation of p53 at Ser-46 by the p53-target gene; p53 regulated
apoptosis inducing protein 1 (p53AIP1), could specifically regu-
late the induction of apoptosis. p53AIP1 was originally isolated as
a p53-target gene using yeast enhancer trap system that allowed
direct cloning of p53-binding sequence from human genomic
DNA in order to isolate p53-target genes. p53AIP1 gene expression
is strongly inducible by DNA damage in a p53-dependent manner,
and is specifically induced after the phosphorylation of p53 pro-
tein at Ser-46, leading to apoptosis (Oda et al., 2000). Importantly,
TP53INP1 induces p53 phosphorylation at Ser-46 and p53AIP1
expression, whereas the inhibition of TP53INP1 expression clearly
impairs p53 phosphorylation at Ser-46 and p53AIP1 expression.
Therefore, TP53INP1 is required for p53 phosphorylation at Ser-
46, the induction of p53AIP1 and apoptosis (Okamura et al., 2001)
(Figure 1).
As p53 is the most important tumor suppressor and p53
mediates cellular stress responses which are disrupted during
tumorigenesis, it is important to further understand the mech-
anisms through which TP53INP1 interacts with HIPK2 and PKCδ
kinases and phosphorylates p53 protein at Ser-46. As there are only
handful studies demonstrating that TP53INP1 forms a complex
with these two kinases to this date, it is important to under-
stand what other co-factors are involved in the protein com-
plexes and how these co-factors promote the formation of the
FIGURE 1 |TP53INP1 induces p53 protein phosphorylation at Ser-46 and
apoptosis after DNA damage. Upon initial DNA damage, p53 is
phosphorylated at Ser-15 and Ser-20, stimulating the binding of p53 to the
promoter regions of a subset of genes such as the G1 arrest gene p21, the
DNA repair gene p53R2 and p53 negative regulators. If DNA damage is
severe, TP53INP1 forms protein complexes with the Ser-46 kinase HIPK2 and
PKCδ, leading to p53 protein phosphorylation at Ser-46, induction of p53AIP1
gene transcription and apoptosis.
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protein complexes and the phosphorylation of p53 protein at
Ser-46.
TP53INP1 INDUCES GROWTH INHIBITION AND APOPTOSIS
IN A p53-INDEPENDENT MANNER THROUGH p73
It has been shown that in the absence of p53, TP53INP1 gene
transcription can be strongly induced by p73, a p53 homolog. p73
is up-regulated in response to cisplatin, gamma-irradiation, and
the oncogene E1A (Das et al., 2003; Hershko et al., 2005), acti-
vates p53-target gene transcription by binding to p53-responsive
elements at p53-target gene promoters (Obad et al., 2004), and
consequently induces cell cycle arrest and/or apoptosis (Jost et al.,
1997; Kaghad et al., 1997). When p53-deficient mice are induced to
suffer from acute pancreatitis or p53-deficient embryonic fibrob-
lasts are treated with cisplatin, a strong DNA damaging agent,
p73 activates TP53INP1 gene transcription, causes cell cycle arrest
and apoptosis in a p53-independent manner (Tomasini et al.,
2005). Using cells from p53-deficient mice, Tomasini et al. (2005)
have demonstrated that the activation of the TP53INP1 gene
promoter by p73 requires the presence of the p53-responsive
element which is located between 1364 and 1239 base pairs
upstream of TP53INP1 transcription start site. This suggests
that p73 overexpression can directly activate TP53INP1 gene
transcription through direct binding to the promoter region of
TP53INP1.
Conversely, TP53INP1 alters the transactivation capacity of p73
on several p53-target genes, including TP53INP1 itself, demon-
strating a functional association between p73 and TP53INP1
(Tomasini et al., 2005). Importantly, when overexpressed in p53-
deficient cells, TP53INP1 activates p73, inhibits cell growth, and
promotes cell death as assessed by cell cycle analysis and colony
formation assays, hence the activation of TP53INP1 could poten-
tially prevent tumor development (Tomasini et al., 2005). It is
worth mentioning that TP53INP1 is able to stimulate p53 activity
at much higher level compared to p73 activity.
INDUCTION OF TP53INP1 GENE EXPRESSION BY E2F1 CAN
BE EITHER p53 DEPENDENT OR INDEPENDENT
E2F1 is a transcription factor, which induces apoptosis via both
p53 dependent and independent mechanisms. E2F1 controls the
expression of a vast number of genes that are essential for pro-
gression from G1 to S phase (Hanahan and Weinberg, 2011). A
study by Hershko et al. (2005) have shown that excessive activ-
ity of E2F1 results in increased expression of TP53INP1 as well
as several other co-factors such as the apoptosis stimulating pro-
teins of p53 (ASPP) family member ASPP1 and ASPP2, and the
pro-apoptotic JMY. Although it is well documented that E2F1
can up-regulate p53 expression (Hershko et al., 2005; Polager
and Ginsberg, 2009), ectopic expression of E2F1 in p53-null
human H1299 lung adenocarcinoma cells results in an increase
in TP53INP1 mRNA (Zemskova et al., 2010). This indicates that
E2F1-mediated up-regulation of TP53INP1 can occur in a p53-
independent manner. Moreover, chromatin immunoprecipitation
assays with primers targeting −415 bp to −121 bp region of the
TP53INP1 gene promoter, confirms that E2F1 directly binds to
TP53INP1 gene core promoter and activates TP53INP1 gene
transcription (Hershko et al., 2005). Given that E2F1 can play
a major role in cell cycle progression and apoptosis, it could
provide very important information to further investigate the
underlying mechanisms responsible for E2F1-induced TP53INP1
expression.
MODULATION OF TP53INP1 EXPRESSION BY
INFLAMMATORY MEDIATORS
Inflammation contributes to the tumor microenvironment by pro-
viding the tumor with essential factors for proliferation, survival,
tumor cell migration, and invasion. Inflammatory mediators play
important roles in tumor initiation and development in certain
cancer types, such as prostate cancer (De Marzo et al., 2007).
TP53INP1 expression has recently been found to be enhanced
in prostate cancer cells after treatment with the pro-inflammatory
mediators tumor necrosis factor α and interleukin 6, indicating
that TP53INP1 overexpression could be involved in inflammation-
mediated prostatic carcinogenesis (Giusiano et al., 2012). In this
scenario, overexpression of TP53INP1 actually results in increased
tumorigenesis, contradicting with the tumor suppressor character-
istic of TP53INP1 as described in various other cancers, suggesting
a tissue specific function. Perhaps, TP53INP1 can act either as a
tumor suppressor gene or an oncogene depending on the tissue
type or the tumor microenvironment.
Micro RNAs REDUCE TP53INP1 mRNA EXPRESSION
MicroRNAs (miRNAs) are a new class of small (21–23 nucleotides)
non-coding RNAs. They function as post-transcriptional regula-
tors of gene expression through base-pairing to complementary
sites on their target mRNAs and are involved in carcinogenesis.
Multiple lines evidences demonstrate that TP53INP1 expression
can be regulated by miRNAs at the post-transcriptional level. For
example, Yeung et al. (2008) have shown that the miRNAs miR-93
and miR-130b, which are up-regulated in HTLV-1–transformed
human T-cell lines, target the 3′ un-translated region (3′UTR)
of TP53INP1 mRNA, and that knocking-down the miRNAs sig-
nificantly increases TP53INP1 mRNA expression and reduces
proliferation and survival of the HTLV-1 infected/transformed
cells (Yeung et al., 2008). In CD133(+) liver tumor-initiating cells,
TP53INP1 is a direct target of miR-130b which promotes cell
growth (Ma et al., 2010).
Tumor protein 53-induced nuclear protein 1 expression can
also be modulated by miR-17-5p and miR-17. While miR-17-5p
suppresses cell growth and promotes apoptosis of cervical cancer
cells, TP53INP1 expression is reduced by miR-17-5p (Wei et al.,
2012). In chronic lymphocytic leukemia (CLL) cells, up-regulation
of miR-17∼92 family miRNAs by Toll-like-receptor-9 agonists is
preceded by a transient induction of the proto-oncogene Myc,
and forced expression of miR-17, a major member from the miR-
17∼92 family, reduces TP53INP1 expression and protects cells
against apoptosis (Bomben et al., 2012).
Additionally, TP53INP1 RNA can be targeted and down-
regulated by miR-155 and miR-125b. miR-155 is overexpressed in
pancreatic cancer cells and interacts with TP53INP1 mRNA at its
3′UTR (Gironella et al., 2007), whereas miR-125b is overexpressed
in type II endometrial carcinoma cells and contributes to the
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malignancy of type II endometrial carcinoma, possibly through
down-regulation of TP53INP1 expression (Jiang et al., 2011). Reg-
ulation of TP53INP1 expression by miR-125b can be potentially
important for more effective therapy, since various studies have
established miR-125b as an oncogene or tumor suppressor gene in
difference types of human tumors (Bousquet et al., 2010; Zhang
et al., 2011; Bhattacharjya et al., 2013).
TP53INP1 INDUCES AUTOPHAGIC CELL DEATH
Autophagy is an important physiological response that is strongly
induced during cellular stress, mainly under nutrient deficiency.
Autophagy is basically a recycling event whereby the cellular
organelles will be engulfed within the autophagosome and bro-
ken down upon contact with lysosome, consequently generating
metabolites used for biosynthesis and energy metabolism to sup-
port the survival of cancer cells in the nutrient limited environ-
ment (Hanahan and Weinberg,2011). Autophagy-related protein 5
(ATG5), beclin-1 and the light chain of the microtubule-associated
protein 1 (LC3, a member of ATG8 family proteins) are key players
in autophagic cell death (White, 2012).
While mainly a nuclear protein, TP53INP1 re-localizes into
autophagosomes during autophagy, where TP53INP1 interacts
with LC3 via a functional LC3-interacting region (Sancho et al.,
2012; Seillier et al., 2012) (Figure 2). As TP53INP1 binds to LC3
with affinity higher than p62, the suppression of which promotes
tumorigenesis (Mathew et al., 2009), TP53INP1 can partially dis-
place p62 from autophagosomes and thus modify the composition
of autophagosomes (Seillier et al., 2012).
Studies with mice with non-functional beclin-1 gene has
shown increased susceptibility to cancer, due to the impairment
in autophagy which requires to be circumvented during tumor
development (Levine and Kroemer, 2008; White and DiPaola,
2009). Importantly, silencing beclin-1 or ATG5 or inhibiting cas-
pase activity, which is necessary for the induction of autophagy,
significantly decreases TP53INP1-induced cell death, indicating
the effect of TP53INP1 in inducing autophagic cell death (Sancho
et al., 2012; Seillier et al., 2012).
TP53INP1 REPRESSES TUMOR CELL MIGRATION
One of the main features of cancer is the capability of cancer
cells to migrate invasively through the stroma to form metastases,
due to the significantly altered expression of the subset of genes
involved in cell to cell and cell to extracellular matrix adhesion
(Hanahan and Weinberg, 2011). TP53INP1 can work as a tumor
suppressor by repressing tumor cell migration during metasta-
sis. Secreted protein acidic and rich in cysteine (SPARC) regulates
tumor cell-matrix interactions, and promotes cancer cell migra-
tion and metastasis (Podhajcer et al., 2008). SPARC gene expres-
sion is up-regulated in normal pancreas in the TP53INP1-deficient
animals, and in pancreatic intraepithelial neoplasia lesions in a
mouse model of pancreatic adenocarcinoma (Seux et al., 2011).
TP53INP1 transcriptionally blocks SPARC gene expression, and
silencing of TP53INP1 increases cell migration in mouse embry-
onic fibroblasts and pancreatic cancer cells (Seux et al., 2011).
Consistent with these findings, miR-125b is overexpressed in
type II endometrial carcinoma cells, and miR-125b expression
increases endometrial carcinoma cell migration through down-
regulating TP53INP1 expression (Jiang et al., 2011). Moreover,
silencing TP53INP1 gene expression significantly correlates with
lymphatic invasion in human gastric cancer patients (Jiang et al.,
2006).
The role of TP53INP1 in suppressing cell migration is also
of particular interest for cancer therapy, since the expression of
genes involved in cell to cell and cell to extracellular matrix adhe-
sion is significantly altered in some highly aggressive carcinomas
(Hanahan and Weinberg, 2011), and TP53INP1 can potentially be
an important player in invasion-metastasis cascade by targeting
the genes. We propose that restoring TP53INP1 gene expression
through targeting its silencers, such as miR-125, could effectively
inhibit tumor invasion and metastasis.
FIGURE 2 |TP53INP1 andTP53INP2 co-operatively induce autophagy.
Under autophagy-inducing stress such as starvation, TP53INP2 translocates
from the nucleus to the autophagosomes, interacts with VMP1, and recruits
the critical autophagy regulator LC3 and beclin-1 (Nowak and Iovanna, 2009).
TP53INP1 interacts with LC3 via a functional LC3-interacting region with
affinity higher than p62, and displaces p62 from autophagosomes.
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TP53INP1 EXPRESSION IS REDUCED IN HUMAN TUMOR
TISSUES AND SILENCING OF TP53INP1 CONTRIBUTES TO
TUMORIGENESIS IN VIVO
Tumor protein 53-induced nuclear protein 1 protein expression
has been found to be present in non-malignant human pancreatic
lesions, but significantly or completely lost in the majority of pri-
mary pancreatic ductal adenocarcinomas and absent in metastatic
tumors (Gironella et al., 2007). Consistently, significant reduc-
tion in TP53INP1 expression has also been detected in human
gastric (Jiang et al., 2006) and colon cancer tissues (Shibuya
et al., 2010). These observations demonstrate that reduction in
TP53INP1 expression might be a general feature of tumor develop-
ment. As knocking-out TP53INP1 gene expression promotes, and
forced overexpression of TP53INP1 reduces, pancreatic and liver
tumorigenesis in mice (Gironella et al., 2007; Ma et al., 2010), the
restoration of TP53INP1 expression could be an effective approach
for cancer therapy.
TP53INP2 EXERTS EFFECTS DISTINCT FROM TP53INP1
Using a bioinformatics approach, Nowak et al. (2005, 2009) have
identified TP53INP2, also known as diabetes and obesity regulated
gene (DOR), as a TP53INP1-related gene. TP53INP2 encodes a
protein with 30% amino acid identity and 45% similarity with
TP53INP1, and shares two highly conserved regions (region 1:
aa residues 28–42; region 2: 66–112 in human) with TP53INP1
(Sancho et al., 2012).
In spite of its homology with TP53INP1, TP53INP2 expression
is not induced by p53, and forced overexpression of TP53INP2
does not alter the cell cycle or apoptosis. However, like TP53INP1,
TP53INP2 is involved in the control of tumor development by
modulating autophagy (Nowak et al., 2009). TP53INP2 func-
tions as a scaffold protein, recruits LC3 and beclin-1 to the
autophagosome through interacting with transmembrane pro-
tein vacuole membrane protein 1 (VMP1) (Nowak and Iovanna,
2009; Nowak et al., 2009), which is essential for autophagy (Ropolo
et al., 2007). Upon autophagy-inducing stress such as starvation,
TP53INP2 translocates from the nucleus to the autophagosomes,
interacts with VMP1, recruits LC3, and beclin-1, but no beclin-2,
and play an important role in autophagy (Nowak and Iovanna,
2009; Nowak et al., 2009) (Figure 2). Additionally, there are
evidences suggesting that TP53INP1 and TP53INP2 can func-
tion as dual regulators of autophagy which make the proteins
even more remarkable in controlling autophagy (Sancho et al.,
2012).
TP53INP2 is also involved in tumor cell migration (Moran-
Jones et al., 2009). Heterogenous nuclear ribonucleoprotein
(hnRNPA2) is an important regulator of alternative splicing, is
up-regulated in some invasive cancer types, and leads to tumor
progression. It has recently been demonstrated that alternative
splicing of exon 2 near the 5′ un-translated region of TP53INP2
is a key event downstream of hnRNPA2 that is necessary for can-
cer cells to migrate and invade through the extracellular matrix
(Moran-Jones et al., 2009).
Despite the important roles of TP53INP2 in cancer cell
autophagy and migration, it is not clear how TP53INP2 expres-
sion is controlled in cancer cells. Additionally, it is important to
understand under which circumstances the splicing of TP53INP2
exon 2 by hnRNPA2 takes place, and whether hnRNPA2 also
regulates alternative splicing of TP53INP1.
CONCLUSION
Tumor suppressive functions of p53 and its homolog p73
reflect physiological activities of a wide range of their tar-
get genes. The identification and functional characteriza-
tion of the critical gene/genes responsible for p53 and p73
induced tumor suppressive functions are very important for
understanding tumorigenesis and for designing better cancer
therapy.
Tumor protein 53-induced nuclear protein 1 gene expres-
sion is often silenced in tumor cells due to oncogenic factors
such as the micro RNAs miR-93, miR-130b, miR-155, miR-125b,
miR-17-5p, and miR-17, which down-regulate TP53INP1 expres-
sion through post-transcriptional mechanisms. Upon exposure to
genotoxic agents, p53 and p73 activates TP53INP1 gene expression
by directly binding to the TP53INP1 gene promoter. Additionally,
the transcription factor E2F1 directly up-regulates TP53INP1 gene
transcription independent of p53 and p73, and the inflammatory
mediators tumor necrosis factor α and interleukin 6 also enhance
TP53INP1 gene expression.
The TP53INP1 gene encodes two protein isoforms, TP53INP1α
and TP53INP1β. Upon initial DNA damage, p53 is phospho-
rylated at Ser-15 and Ser-20, stimulating the binding of p53 to
promoter regions of a subset of genes such as the G1 arrest
genes p21, the DNA repair gene p53R2, and the p53 negative
regulators such as MDM2. If DNA damage is severe, TP53INP1
forms protein complexes with the protein kinases HIPK2 or
PKCδ to phosphorylate p53 at Ser-46, promoting the bind-
ing of p53 to the promoter regions of apoptosis related genes
such as p53AIP1 rather than the repair related genes, leading
to cell growth arrest and apoptosis (Figure 1). Additionally,
TP53INP1 facilitates p73-mediated apoptosis independent of p53,
enhances autophagic cell death by interacting with LC3, and
represses tumor cell migration via regulating SPARC expression.
As TP53INP1 expression is frequently silenced or completely lost
in human cancer tissues, restoration of TP53INP1 expression
could potentially inhibit tumor growth via its anti-proliferative,
pro-apoptotic, pro-autophagic, and anti-cell migration activities.
While TP53INP1 expression can be indirectly up-regulated by
chemicals which activate p53 expression, we anticipate that small
molecule compounds which activate TP53INP1 gene promoter
activity through binding to p53-binding sites could potentially
restore TP53INP1 expression, and the small molecule compounds
could be discovered through screening small molecule compound
libraries.
The TP53INP1-related gene TP53INP2 has recently been iden-
tified. Unlike TP53INP1, TP53INP2 expression is not modulated
by p53, and TP53INP2 does not modulate cell cycle progression
and apoptosis. While TP53INP2 induces autophagy via mech-
anisms similar to TP53INP1, an alternative splicing product of
TP53INP2 RNA due to hnRNPA2 induces cancer cell migration.
It is crucial to further understand how to control hnRNPA2-
mediated TP53INP2 splicing to avoid cancer cell migration,
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and to retain TP53INP2-mediated autophagy, which synergizes
with TP53INP1-induced autophagy. As such, restoration of
TP63INP1 and TP53INP2 expression without the induction of
hnRNPA2-mediated TP53INP1 RNA alternative splicing would
ideally induce cancer cell cycle arrest, apoptosis, and autophagy,
therefore simultaneously inducing binary cell death for a more
effective therapy.
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